POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET ANALYSIS

Post-traumatic Stress Disorder Treatment Market, by Drug Class (Antidepressants, Anti-anxiety, Antihypertensive, Monoamine Oxidase (MAOs), Antipsychotics or Second Generation Antipsychotics (SGOs), Beta-Blockers, and Others (Benzodiazepines and Others)), by Route of Administration (Oral, Parenteral, and Nasal), by Age Group (Pediatric, Adult, and Geriatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Dec 2022
Code : CMI4433
Pages :183
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Post-traumatic Stress Disorder Treatment Market: Key Developments

In May 2020, Allied Corp., a pharmaceutical company, announced the signing of a manufacturing and distribution agreement with MGC Pharmaceuticals, a pharmaceutical company. According to the agreement, MGC Pharmaceuticals will manufacture Allied Corp.’s products. MGC currently has cannabis-based pharmaceutical products for sale in Europe and has demonstrated a proven ability to commercialize these products. Commercialization of Allied’s post-traumatic stress disorder (PTSD) treatment products into the European, Latin America, and North American marketplace is a key strategy of Allied’s

On November 4, 2019, Bionomics limited, a global clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the BNC210 development program for the treatment of post-traumatic stress disorder (PTSD) and other trauma-related and stressor-related disorders.

In October 2020, Jazz Pharmaceuticals plc, a pharmaceutical company, and SpringWorks Therapeutics, Inc., a biotechnology company, announced that Jazz Pharmaceuticals Ireland Limited and SpringWorks entered into an asset purchase and exclusive license agreement under which Jazz had acquired SpringWorks' Fatty Acid Amide Hydrolase ("FAAH") inhibitor program including PF-04457845 in US$ 375 million. Jazz will initially focus on developing PF-04457845 for the potential treatment of PTSD and associated symptoms. PF-04457845 represents an innovative approach to treating PTSD with a novel mechanism of action that has the potential to address multiple core symptoms of the disease, including fear extinction, anxiety, and disrupted sleep architecture.

Post-traumatic Stress Disorder Treatment Market Report Snapshots